Novo Nordisk has entered into settlement agreements with several manufacturers that have filed ANDAs for Victoza®. Consequently, these manufacturers are licensed to launch a generic version of Victoza® as of 22 June 2024, or earlier under certain circumstances. Moreover, Novo Nordisk has entered into a settlement agreement with Teva Pharmaceuticals USA, Inc., regarding the US patent litigation case for Saxenda®. All terms of the agreement are confidential. All agreements are subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

 

1,Novo Nordisk.